Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting
September 22, 2020

The ODM DUR Board meeting was called to order at 12:00 PM EST via GoToMeeting
https://attendee.gotowebinar.com/register/4191752150770894095

Michael Dietz, D.O. presided

The following Board members were present:
  Scott Baran, R.Ph.
  David Brookover, R.Ph.
  Michael Dietz, D.O., Chair
  Michael Farrell, M.D.
  Robert Kubasak, R.Ph.
  A. Mehran Mostafavifar, M.D.
  Lenard G. Presutti, D.O.
  Stacey Rexrode-Brewer Pharm.D., Co-Chair
  Donald Sullivan Ph.D., R.Ph.

Also present from ODM were Tracey Archibald, Pharm.D., Michelle Barger, Pharm.D., Sean Eckard, B.S.
Pharm. D. Change Healthcare attendees included Jill R.K. Griffith B.S. Pharm. D., Gail Master, R.Ph., and
Philip Verret, Pharm.D. Approximately 35 observers were present.

The Conflict of Interest Statement

The Conflict of Interest Statement was reviewed with the Board.

Roll Call and Review of Previous Minutes

The May 12, 2020 DUR Board Meeting Minutes were approved.

DUR Committee Report

G. Master presented re-review results from the intervention directed at prescribers whose patients were 18
years old and younger who were 70% or less adherent to their atypical antipsychotic medication. She then
presented re-review results from the intervention directed at prescribers whose patients were older than 18
years who were 50% or less adherent to their atypical antipsychotic medication.

Next, G. Master presented re-review of the package size edit. She explained the rationale for placing an edit
in the point of sale for nitroglycerin sublingual tablets. A discussion ensued about the quantity written on a
prescription versus the bottle size. The Board agreed with this edit.

Lastly, G. Master provided an update to the Board on Coordinated Services Program (CSP) membership. There
are currently 221 Fee-for-Service members enrolled in the program.

Lastly, G. Master provided an update on the 2020 Volume 12 DUR Digest that is posted to the Ohio Pharmacy
Medicaid website.
Health Plan Policy Update

S. Baran presented the Medicaid Health Plan Policy update. He stated COVID-19 continues to be a focus for ODM. In ongoing reaction to this declared state of emergency, ODM has been working on implementing COVID-19 Point of Care testing strategies in pharmacies. Current discussions involve preferred testing modalities and reimbursement. The goal is for these claims to be submitted similar to existing vaccine logic by using a pharmacy (NCPDP) claim. A new ‘professional service code’ (PT code) will be used to indicate that the pharmacy collected the specimen and performed an analysis on-site. Finalized details of this effort will be available soon.

Next, S. Baran said another project ODM is working on is for Pharmacists to become enrolled as Providers. ODM is currently engaging stakeholders and working on rule language. ODM Pharmacy is collaborating with the ODM Managed Care Policy team to communicate efforts and expectations with their Managed Care Organizations (MCOs). S. Baran said ODM is also developing educational programs for prospective providers on topics including enrollment, Medicaid rules, and claims submission.

Next, S. Baran stated the Centers for Medicare and Medicaid Services (CMS) has issued the Federal Fiscal Year (FFY) 2019 Annual DUR Report to the states. Like last year’s survey, it includes information on both FFS and MCO DUR programs. ODM will communicate once the final report is posted to the Medicaid.gov website, which they anticipate will be later this year.

Next, S. Baran reminded everyone that the next P&T Committee meeting will take place on September 30th beginning at 9am. This is the Annual Unified Preferred Drug List (UPDL) meeting where the Committee reviews the entire UPDL document. The meeting will be a virtual webinar and attendees may register on the ODM Pharmacy website. Also, ODM is planning to update the UPDL format. This new appearance is a simpler design intended to be more user-friendly for providers.

Also, S. Baran announced that in an effort to align diabetic testing supplies among FFS and MCOs, ODM is adding a requirement to the January 2021 Provider Agreement requiring MCOs to cover the same Diabetic Blood Glucometers and Blood Glucose Test Strips as FFS. Similar to the UPDL effort, by standardizing diabetic testing supplies the goal is to decrease member and provider confusion by streamlining this process.

Next, S. Baran explained every two years ODM conducts a Cost of Dispensing Survey. This survey is administered to ODM enrolled pharmacies and a final report with the findings is generated and posted on the Medicaid Pharmacy website. The survey has been distributed and responses are due by September 24th.

Lastly, S. Baran announced that ODM has posted two pharmacologist positions to join their growing Pharmacy team. Further details about these postings can be found on the careers.ohio.gov jobs portal website.

Unfinished Business

There was no unfinished business.

New Business

G. Master provided an overview of a RetroDUR intervention that notified prescribers that their patients were taking opioid medications(s) in combination with a stimulant. The Board reviewed the letter. She then presented an intervention where a fax was sent to pharmacy providers which reminded them to
vaccinate their Ohio Medicaid patients with a flu shot. The Board reviewed the fax.
Next, Dr. Eckard presented a summary of how ODM is preparing for the COVID-19 point of care testing in pharmacies.
Lastly, G. Master announced that ODM is reviewing their current coverage and utilization of bulk powders and excipients that are used in compounds. Currently, work is underway to update this list and more information on this project will be shared at the November meeting.

Announcements

The dates for the next DUR Board meetings were set as follows:
  • November 10, 2020
  • February 9, 2021

G. Master reviewed the remaining 2020 tentative calendar of interventions. A discussion ensued around an intervention for patients taking multiple antipsychotic medications.

Adjournment

The meeting was adjourned at 1:12 PM.